CE09 - Nanomatériaux et nanotechnologies pour les produits du futur

A nanofluidic bar code – NANOCODE

Submission summary

In the field of biomedical analysis, current macroscopic methods based on chromatography techniques coupled to mass spectrometry remain long and tedious, which may prove detrimental for certain pathologies such as innate errors of metabolism where a fast and early diagnosis is often desired. On-chip analytical methods are therefore very promising, since analysis can be carried out in less than 30 minutes with a microliter of cerebrospinal fluid (CSF). By associating a new electrophoresis protocol, we have demonstrated that a "barcode" nanofluidic biochip allows identification and concentration of the analyte in a few minutes by a single space-time mapping of the fluorescent focal points.
With a portable analysis bench integrating this new nanofluidic barcode chip, the NANOCODE project proposes diagnosing innate deficits in dopamine and serotonin by assaying their metabolites as well as the enzymatic cofactors, the pterins involved in their biosynthesis, in the CSF thanks to this new nanofluidic barcode chip and a portable analysis bench.

The project is divided into 4 main lines of research:

• 1rst scientific Challenge: Development of protocols for the preparation of CSF samples from patients with EIM disorders. The preparation of CSF samples before their injection into the chip will be optimized. Two detection modes will be studied during the project: (1) the classical fluorescence, which imposes a labeling by derivation of the target molecules, and (2) UV spectroscopy using a miniaturized fiber system, that is more original and innovative, because it allows to remove the marking step, thus simplifying the sample preparation step.

• 2nd scientific challenge: Definition of an optimal pressure-assisted electro-preconcentration protocol - towards the best bar-code geometry: the parameters (Electric field and pressure) of the pressure-assisted electro-preconcentration will be optimized to obtain "barcodes", over short times of several minutes, with stable focal points 1000 times concentrated.

• Technical challenge n° 3: Miniaturization of the electrophoresis bench and development of a low-cost fabrication process for biochips. We will develop a miniaturized electro-preconcentration platform with double-detection (fluorescence and absorption spectroscopy in the UV) and a nanostructuration process of low-cost glass chips based on nanoimpression.

• 4rd scientific challenge: Validation of one or more electro-preconcentration protocols on real solutions from a dozen patients. From hospital-supplied CSF samples, we aim to quantify targeted biomarkers in the form of characteristic barcodes that will be compared to conventional HPLC-MS analyzes.

At the end of the NANOCODE project, in the field of IEMs, our aim is to propose a rapid diagnosis method of the "Relocated Biology" type, similar to what is currently practiced in the field of medical emergencies (blood glucose levels, blood pH and electrolytes, cardiac markers, CRP, PCT and pathogen search). In terms of valorization, the NANOCODE project with the complementary skills of its 3 partners would allow a rise in TRL of this new disruptive technology. During the last year of the project, in addition to additional patent filings, we will seek to raise funds for valorization calls with a goal of creating a start-up.

Project coordination

Anne-Marie Haghiri (Centre de Nanosciences et de Nanotechnologies)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


LCP Laboratoire de Chimie Physique
Lip(Sys)2 Lipides : Systèmes analytiques et biologiques
C2N Centre de Nanosciences et de Nanotechnologies

Help of the ANR 373,626 euros
Beginning and duration of the scientific project: March 2019 - 36 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter